부산대학교 도서관

Simple Summary: Multi-gene expression assays have been advocated for treatment decision in breast cancer management. The most commonly used assays such as Oncotype DX, MammaPrint, which were developed from the Western population, were especially designed for the prognostication of early stage luminal-type breast cancer. The tabulation of multi-gene expression assay and clinical risk has become the research interest recently. The 23-gene signature was purposed for the Asian population and was validated for the discriminative ability regarding 5-year relapse-free survival and the objective of this study was to evaluate the performance across distinct clinical risk groups. Background: A 23-gene classifier has been developed based on gene expression profiles of Taiwanese luminal-like breast cancer. We aim to stratify risk of relapse and identify patients who may benefit from adjuvant chemotherapy based on genetic model among distinct clinical risk groups. Methods: There were 248 luminal (hormone receptor-positive and human epidermal growth factor receptor II-negative) breast cancer patients with 23-gene classifier results. Using the modified Adjuvant! Online definition, clinical high/low-risk groups were tabulated with the genetic model. The primary endpoint was a recurrence-free interval (RFI) at 5 years. Results: There was a significant difference between the high/low-risk groups defined by the 23-gene classifier for the 5-year prognosis of recurrence (16 recurrences in high-risk and 3 recurrences in low-risk; log-rank test: p < 0.0001). Among the clinically high-risk group, the 5-year RFI of high risk defined by the 23-gene classifier was significantly higher than that of the low-risk group (15 recurrences in high-risk and 2 recurrences in low-risk; log-rank test: p < 0.0001). Conclusion: This study showed that 23-gene classifier can be used to stratify clinically high-risk patients into distinct survival patterns based on genomic risks and displays the potentiality to guide adjuvant chemotherapy. The 23-gene classifier can provide a better estimation of breast cancer prognosis which can help physicians make a better treatment decision. [ABSTRACT FROM AUTHOR]